The Clinical Value Of GP73 As A Biomarker For Diagnosis Of Liver Carcinoma

Primary Hepatocellular Carcinoma (PHC) is the fifth leading cause of cancer death worldwide.Several serum biomarkers of HCC have been described, but better markers with improved sensitivity and specificity are being sought.Recent studies have identified GP73 and fucosylated GP73 in the sera of patients with liver disease, particularly HCC had sensitivities of 69%&90%and specificities of 90%&100%.Their efficiencies are significantly higher.However,it takes a while to evaluate whether the test is on fact and to use them for diagnosis of HCC in clinic.(1) Background:Golgi protein 73(GP73) is a candidate serum marker of liver disease,especially liver carcinoma.The purpose of this study was to measure serum GP73 in patients with hepatitis, cirrhosis, liver carcinoma and in healthy individuals,and to validate GP73 as a biomarker for early diagnosis of liver carcinoma.(2) Methods:Using an enzyme-linked immunosorbent assay(ELISA),serum GP73 was quantified from 311 patients with hepatitis, cirrhosis,liver carcinoma and in healthy individuals.(3) Results:The GP73 level in patients with liver disease was significantly higher than in healthy individuals. GP73 had a sensitivity of 94.7%and a specificity of 96.2% as a biomarker for early diagnosis of liver carcinoma. (4) Conclusion:sGP73 concentration in patients with liver disease was significantly higher than in healthy individuals.These results suggest that sGP73 and AFP may be used as serum markers for the diagnosis of liver disease.